These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16651477)

  • 1. Images in cardiovascular medicine. Implantation of a drug-eluting stent for the coronary artery stenosis of Takayasu arteritis: de novo and in-stent restenosis.
    Kang WC; Han SH; Oh KJ; Ahn TH; Shin EK
    Circulation; 2006 May; 113(17):e735-7. PubMed ID: 16651477
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful management of left main coronary artery stenosis with a paclitaxel-eluting stent in Takayasu's arteritis.
    Kang WC; Han SH; Ahn TH; Shin EK
    Int J Cardiol; 2006 Mar; 108(1):120-3. PubMed ID: 16516707
    [No Abstract]   [Full Text] [Related]  

  • 3. Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions.
    Iofina E; Langenberg R; Blindt R; Kühl H; Kelm M; Hoffmann R
    Am J Cardiol; 2006 Oct; 98(8):1022-7. PubMed ID: 17027564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.
    Kitoga M; Pasquet A; Preumont V; Kefer J; Hermans MP; Vanoverschelde JL; Buysschaert M
    Diabetes Metab; 2008 Feb; 34(1):62-7. PubMed ID: 18069029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
    Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schömig A
    Circulation; 2006 May; 113(19):2293-300. PubMed ID: 16682614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry.
    Buszman P; Trznadel S; Milewski K; Rzeźniczak J; Przewłocki T; Kośmider M; Wójcik J; Janczak J; Zurakowski A; Kondys M; Król M; Kinasz L; Jaklik A; Rzeszutko Ł; Kałuza GL; Kiesz S; Gil R
    Catheter Cardiovasc Interv; 2008 Jan; 71(1):51-7. PubMed ID: 18098182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated coronary revascularization with drug-eluting stents: immediate and seven-month outcome.
    Vassiliades TA; Douglas JS; Morris DC; Block PC; Ghazzal Z; Rab ST; Cates CU
    J Thorac Cardiovasc Surg; 2006 May; 131(5):956-62. PubMed ID: 16678575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings.
    Aoki J; Kirtane AJ; Dangas GD; Lansky AJ; Morales A; Kimura M; Kim YH; Moussa I; Weisz G; Kreps EM; Collins M; Frankin-Bond T; Stone GW; Moses JW; Leon MB; Mehran R
    Am J Cardiol; 2008 Jan; 101(1):58-62. PubMed ID: 18157966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel-eluting balloon: from bench to bed.
    De Labriolle A; Pakala R; Bonello L; Lemesle G; Scheinowitz M; Waksman R
    Catheter Cardiovasc Interv; 2009 Apr; 73(5):643-52. PubMed ID: 19309715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary collateral function long after drug-eluting stent implantation.
    Meier P; Zbinden R; Togni M; Wenaweser P; Windecker S; Meier B; Seiler C
    J Am Coll Cardiol; 2007 Jan; 49(1):15-20. PubMed ID: 17207716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
    Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB;
    Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease.
    Barlis P; Kaplan S; Dimopoulos K; Ferrante G; Di Mario C
    Cardiology; 2008; 111(4):270-6. PubMed ID: 18451644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravascular ultrasound assessment of drug-eluting stent expansion.
    de Ribamar Costa J; Mintz GS; Carlier SG; Fujii K; Sano K; Kimura M; Tanaka K; Costa RA; Lui J; Na Y; Castellanos C; Biro S; Moussa I; Stone GW; Moses JW; Leon MB
    Am Heart J; 2007 Feb; 153(2):297-303. PubMed ID: 17239693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis.
    Kim YH; Dangas GD; Solinas E; Aoki J; Parise H; Kimura M; Franklin-Bond T; Dasgupta NK; Kirtane AJ; Moussa I; Lansky AJ; Collins M; Stone GW; Leon MB; Moses JW; Mehran R
    Am J Cardiol; 2008 Mar; 101(6):801-6. PubMed ID: 18328844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus-eluting stent showed better one-year outcomes than paclitaxel-eluting stent in a real life setting of coronary intervention in Koreans.
    Suh JW; Park JS; Cho HJ; Kim MS; Kang HJ; Cho YS; Koo BK; Chung WY; Youn TJ; Chae IH; Choi DJ; Kim HS; Sohn DW; Oh BH; Park YB
    Int J Cardiol; 2007 Apr; 117(1):31-6. PubMed ID: 17292498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
    Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
    J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.
    Jeong YH; Hong MK; Lee CW; Park DW; Kim YH; Kim JJ; Park SW; Park SJ
    Int J Cardiol; 2008 Mar; 125(1):36-40. PubMed ID: 17521753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiographic and intravascular ultrasound study of the effects of overlapping sirolimus- and paclitaxel-eluting stents: comparison with same drug-eluting overlapping stents.
    Kang WC; Oh KJ; Han SH; Ahn TH; Chung WJ; Shin MS; Koh KK; Choi IS; Shin EK
    Int J Cardiol; 2007 Dec; 123(1):12-7. PubMed ID: 17289176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.